Diede Brunen

Diede Brunen is a Senior Associate at BGV and played an instrumental role in the inception of Genase Therapeutics. He has extensive experience in translational biomedical research, spanning the areas of oncology and immunology. Diede performed his PhD research in the group of prof. René Bernards at The Netherlands Cancer Institute in Amsterdam, during which he used genetic screens to identify novel synthetic lethality targets. Prior to that he completed the master’s program Infection & Immunology at Utrecht University (cum laude), of which he spent one year conducting research at the Hospital for Sick Children in Toronto, Canada. His research and review articles have been published in several high-impact journals. Diede is currently board observer for Genase Therapeutics, Dunad Therapeutics, Tiga Therapeutics, and three stealth companies.